TTD | Drug: D05UGJ

Drug General Information
Drug ID	D05UGJ
Former ID	DCL000017
Drug Name	XL844
Drug Type	Small molecular drug
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Discontinued in Phase 1	[521743]
Therapeutic Class	Anticancer Agents
Company	Exelixis
Formula	C14H17N5O2
Canonical SMILES	C1=CC=C(C(=C1)NC(=O)NC2=NC=CN=C2)OCCCN
InChI	1S/C14H17N5O2/c15-6-3-9-21-12-5-2-1-4-11(12)18-14(20)19-13-10-16-7-8-17-13/h1-2,4-5,7-8,10H,3,6,9,15H2,(H2,17,18,19,20)
InChIKey	UVSSZSQSZGKMAL-UHFFFAOYSA-N
PubChem Compound ID	10016910
PubChem Substance ID	14997810, 22447341, 44109005, 74454073, 134338730, 139620218, 142994715, 239497091, 247769857
Target and Pathway
Target(s)	Serine/threonine-protein kinase Chk2	Target Info	Modulator	[1572591]
Target(s)	Serine/threonine-protein kinase Chk1	Target Info	Modulator	[1572591]
KEGG Pathway	Cell cycle
	p53 signaling pathway
	HTLV-I infectionhsa04110:Cell cycle
	HTLV-I infection
	Viral carcinogenesis
Pathway Interaction Database	ATM pathway
	FOXM1 transcription factor network
	p53 pathway
	PLK3 signaling eventsfanconi_pathway:Fanconi anemia pathway
	p73 transcription factor network
	ATR signaling pathway
	Circadian rhythm pathway
Reactome	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
	G2/M DNA damage checkpoint
	Ubiquitin Mediated Degradation of Phosphorylated Cdc25AR-HSA-176187:Activation of ATR in response to replication stress
	Processing of DNA double-strand break ends
	Presynaptic phase of homologous DNA pairing and strand exchange
	Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
WikiPathways	DNA Damage Response
	ATM Signaling Pathway
	Integrated Pancreatic Cancer Pathway
	Prostate Cancer
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Cell Cycle
	miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
	Signaling by SCF-KIT
	Retinoblastoma (RB) in Cancer
	Cell Cycle Checkpoints
	miRNA Regulation of DNA Damage Response
References
Ref 521743	ClinicalTrials.gov (NCT00234481) Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
Ref 1572591	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

Drug Information